The Board of Directors at its meeting held today, have inter alia, transacted the following items of business and taken the decisions as under: 1. Approved the Audited Financial Results ....
GUJTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 5.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved audited financial results for Q4 and full year ended March 31, 2026. Total income grew 9.8% to ₹16,825 Lakhs from ₹15,323 Lakhs. However, profit before tax declined 5.3% to ₹6,209 Lakhs (vs ₹6,554 Lakhs), mainly due to significantly higher finance costs (₹295 Lakhs vs ₹36 Lakhs) and doubled depreciation (₹1,292 Lakhs vs ₹537 Lakhs). PAT declined 4.3% to ₹4,668 Lakhs. The company also declared a dividend of ₹0.67 per share and approved a preferential issue of equity shares to non-promoters, subject to shareholder and regulatory approvals. Significant capital expansion is underway with ₹17,253 Lakhs invested in property, plant and equipment during the year.
PAT declined year-on-year despite revenue growth, indicating margin pressure from higher depreciation and finance costs due to heavy debt-funded expansion. The proposed preferential issue will dilute existing shareholders. Investors should monitor the company's ability to monetize its expansion given the significant increase in borrowings from ₹2,964 Lakhs to ₹12,806 Lakhs.